CGNX.NASDAQCognex CORP

Form 4: Cognex Corp Executive Sheila DiPalma Reports Stock Option Grant and RSU Award

Sentiment:

SEC Form 4 Filing


Sheila Marie DiPalma, EVP of Employee Services at Cognex Corp, reports the acquisition of stock options and restricted stock units (RSUs) in a recent Form 4 filing.

Summary

  • Sheila Marie DiPalma, an Executive Vice President at Cognex Corp, filed a Form 4 with the SEC.
  • The filing reports the grant of non-qualified stock options to purchase 41,460 shares of Cognex common stock at an exercise price of $33.04, vesting annually over five years starting February 18, 2026.
  • DiPalma also received 15,134 restricted stock units (RSUs), each representing a contingent right to receive one share of Cognex common stock, vesting 20%, 30%, and 50% on the first, second, and third anniversaries of the grant date (February 18, 2025), respectively.
  • The filing also lists previously held derivative securities, including stock options and RSUs, with varying exercise prices and expiration dates.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The filing reflects standard executive compensation practices, which are generally viewed favorably as they align management's interests with shareholders.

Positives

  • The grant of stock options and RSUs aligns DiPalma's interests with those of Cognex shareholders.
  • The vesting schedules of the options and RSUs incentivize long-term performance and retention.

Industry Context

Stock option and RSU grants are common forms of executive compensation in the technology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

  • Executive compensation packages, including stock options and RSUs, are common practice among publicly traded technology companies like Cognex.
  • Companies such as Keyence, Omron, and National Instruments also utilize similar equity-based compensation to incentivize their executives.
  • The specific terms of the grants, such as vesting schedules and exercise prices, are typically benchmarked against industry peers to ensure competitiveness.

Stakeholder Impact

  • The stock option and RSU grants could have a slightly dilutive effect on existing shareholders.
  • The grants incentivize the executive to improve company performance, which benefits all stakeholders.

Key Dates

DateDescription
02/21/2018Date of Non-Qualified Stock Option grant with an exercise price of $38.39, expiring on 02/21/2027.
02/19/2020Date of Non-Qualified Stock Option grant with an exercise price of $51.49, expiring on 02/19/2029.
02/18/2021Date of Non-Qualified Stock Option grant with an exercise price of $50.94, expiring on 02/18/2030.
02/22/2023Date of Non-Qualified Stock Option grant with an exercise price of $64.43, expiring on 02/22/2032 and Restricted Stock Unit grant vesting on 02/22/2025.
02/21/2024Date of Non-Qualified Stock Option grant with an exercise price of $47.21, expiring on 02/21/2033 and Restricted Stock Unit grant vesting on 02/21/2026.
02/20/2025Date of Non-Qualified Stock Option grant with an exercise price of $39.44, expiring on 02/20/2034 and Restricted Stock Unit grant vesting on 02/20/2027.
02/18/2025Date of Non-Qualified Stock Option grant with an exercise price of $33.04, expiring on 02/18/2035 and Restricted Stock Unit grant vesting on 02/18/2026, 02/18/2027, and 02/18/2028.
10/30/2025Date of Non-Qualified Stock Option grant with an exercise price of $65.9, expiring on 10/30/2030.

Keywords

Form 4, Cognex, Stock Options, Restricted Stock Units, RSU, CGNX, Sheila DiPalma, Executive Compensation, Insider Trading

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.